TrialBreast cancer research and treatment2016

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study.

L M Smyth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.